Immunomedics (NASDAQ:IMMU) Director David M. Goldenberg sold 20,000 shares of the stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total transaction of $350,000.00. Following the completion of the transaction, the director now owns 1,774,285 shares of the company’s stock, valued at $31,049,987.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
IMMU stock traded down $0.69 on Friday, hitting $13.94. 1,608,244 shares of the company’s stock traded hands, compared to its average volume of 2,253,739. Immunomedics has a 1-year low of $5.00 and a 1-year high of $18.93. The firm has a market cap of $2,536.34, a PE ratio of -17.21 and a beta of 1.62. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 1.26.
Immunomedics (NASDAQ:IMMU) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. sell-side analysts expect that Immunomedics will post -0.96 earnings per share for the current year.
Large investors have recently modified their holdings of the stock. Calton & Associates Inc. purchased a new stake in shares of Immunomedics in the 4th quarter valued at approximately $135,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Immunomedics in the 4th quarter valued at approximately $193,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of Immunomedics by 11.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 1,473 shares in the last quarter. Sapphire Star Partners LP purchased a new stake in shares of Immunomedics in the 4th quarter valued at approximately $323,000. Finally, SG Americas Securities LLC lifted its position in shares of Immunomedics by 27.2% in the 3rd quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock valued at $368,000 after acquiring an additional 5,631 shares in the last quarter. Institutional investors and hedge funds own 74.51% of the company’s stock.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.